Sep 12, 2023 / 01:30PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hey, everyone. Good morning. Thank you for joining us. My name is Tejas Savant, I cover Life Science Tools and Diagnostics here at Morgan Stanley.
Before we begin, I'd like to remind investors that important disclosure information can be found at morganstanley.com/researchdisclosures. Before -- Yes, so it's my pleasure today to have the Chairman, CEO and President of Hologic, Steve MacMillan here on stage with me. Thank you for joining us, Steve.
Stephen P. MacMillan - Hologic, Inc. - Chairman, CEO & President
Thanks for having us, Tejas.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystLots to chat about so let's get right to it. I'll start with the core diagnostics franchise, right? So as you think about the COVID sales unwinding, you've seen strong growth in the non-COVID piece of the portfolio. I think the guide embed something like low double-digit growth this year. How